Pathology and Diagnostics News

Filtered by March 2021 Remove date search

  • Pathology Product Roadmap and meeting schedule published

    Dear all,

    In line with our recently updated Pathology and Diagnostics Product Roadmap we have published a meeting and events schedule which shows all of our forthcoming planned release dates for the Unified Test List for the next fiscal year. The calendar also shows upcoming dates for the Pathology Informatics National User Group (PINUG), Pathology Standards Governance Board (PSGB) and the Pathology Programme Board (PPB)

    If you would like to be added to the PINUG distribution list to receive invitations for the meetings, please email Pathologyanddiagnostics@nhs.net

    The information below provides an overview of the function of the PINUG (open group) and our advisory and decision-making boards:

     

    Pathology Informatics National User group (PINUG)

    The Pathology Informatics National User Group will have a membership drawn from organisations and regions covering NHS and Arm’s Length Bodies, laboratories, healthcare system suppliers and other relevant stakeholders.

    The fundamental purpose of the PINUG will therefore be to ensure:

    • Pathology product backlog is prioritised and assessed from a user impact and business value perspective to support NHS Digital Pathology Product Owner decision making.
    • Feedback on the Unified Test List (UTL), Units of Measure (UoM), Information Model and Pathology FHIR profiles are provided and relevant business activity across the reporting period is discussed.
    • Identify suitable candidates to support user research or user story elaboration from a user perspective.

    Pathology Standards Governance Board (PSGB)

    The purpose of the Pathology Standards Governance Board (PSGB) is to ensure a high quality UTL containing SNOMED CT concepts and processes for maintaining them to ensure they are clinically safe, accepted and effective for the user community.

    The objectives are:

    • Execute oversight of the pathology standard (UTL) for reporting pathology test requests and results.
    • Approve the UTL releases, including new test requests and results and retiring inactivated codes.
    • Provide recommendations to IReS on UTL related products and service developments including:

    -         Test request and result names and codes

    -         Units of Measures

    -         Central repositories/APIs of UTL

    -         Review tracking tools associated with clinical assurance of the UTL and associated products.

    • Recommend priorities for UTL development.
    • Oversee the clinical and technical assurance of the UTL releases and the associated UoM.
    • Oversee the clinical and technical assurance processes used to maintain the quality of UTL.
    • Approve and oversee the maintenance of the Editorial Principles for the UTL
    • Facilitate the expansion of the UTL, as required for the pathology disciplines, in consultation with stakeholders.
    • Promote uptake and use within the user community.
    • Provide leadership in acceptance and integration of the UTL deployment in the NHS aligned with the mandatory requirements identified by NHS England and NHS Improvement’s National Pathology Optimisation and Delivery board

    Pathology Programme Board (PPB)

    The role of the Pathology Programme Board is to own the high-level roadmap to enable the sharing of Pathology test results within the NHS and ensure the programme is operating to a central vision and common objectives.

    The Pathology Programme Board is responsible for:

    • Providing overall direction for the CCIO7 Pathology Programme, ensuring clear objectives and defined deliverables are set.
    • Committing resources to ensure the successful completion of the programme.
    • Prioritising deliverables and resources
    • Resolving strategic and directional cross-organisational/stakeholder issues or dependencies.
    • Ensuring effective engagement and communications with external stakeholders across the NHS.
    • Informing the Senior Responsible Owners, Decision Making

    Kind regards

    National Pathology and Diagnostics

    NHS Digital

    By Chris Hood 1 year ago

    Read this article

  • UTL v0.7.0 released

    UTL v0.7.0 

    In line with the NHS Digital Pathology and Diagnostics Product Roadmap we are pleased to announce that V0.7.0 of the Unified Test List has now been published both in human-readable form on our collaboration space and as machine-readable (RF2) format on TRUD .

    This release includes the following domains:

    • Chemical pathology
    • Endocrinology
    • Toxicology
    • Andrology
    • Haematology
    • Immunology
    • Microbiology

    The Human readable release now has 3677 concepts in total and the Machine readable release has 3162.

    The release is provided in two parts:

    1. Outstanding PBCL (Pathology Bounded Code List) codes
    2. Concepts representing the “qualitative interpretation of presence” (Human readable release only)

    The following are not included in this release:

    • Small batches of PBCL content identified by laboratory / clinical experts as obsolete, erroneous, or requiring further review.
    • PBCL content already existing in the SNOMED CT UK clinical extension that are acceptable representations in line with UTL.
    • New requestable codes will be included in a future update release.

    The concepts representing the “qualitative interpretation of presence” was flagged as an area that may be ambiguous in use, as the value attached could potentially be overlooked, for example:

    Presence of HIV 1 RNA by NAAT = negative (value)

    To establish a consensus from users and stakeholders we have published this terminology pattern alongside the main content but separate from the core terminology recorded in the machine-readable form, to solicit further beta feedback on the preferred pattern for these concepts.

    The columns for the attributes including substance, property and specimen are included purely for information. They will ultimately be used to formally classify the SNOMED content using the observable entity concept model, where the attributes and corresponding values will be used to create the SNOMED CT machine readable description logic definitions

    Please use the links below to access the updated supporting documentation:

     Please provide feedback via: 

    As a Pathology and Diagnostics stakeholder, you will have received an invitation for a kick-off meeting and workshop, on 25th March and 8th April respectively, where the team will provide an overview of the release and aim to address any feedback received.

    By Chris Hood 1 year ago

    Read this article